Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

bioAffinity Technologies Q3 EPS $(4.74) Misses $(2.70) Estimate, Sales $1.446M Beat $1.411M Estimate

Author: Benzinga Newsdesk | November 14, 2025 08:13am
bioAffinity Technologies (NASDAQ:BIAF) reported quarterly losses of $(4.74) per share which missed the analyst consensus estimate of $(2.70) by 75.56 percent. This is a 1.25 percent increase over losses of $(4.80) per share from the same period last year. The company reported quarterly sales of $1.446 million which beat the analyst consensus estimate of $1.411 million by 2.48 percent. This is a 38.47 percent decrease over sales of $2.350 million the same period last year.

Posted In: BIAF


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist